Erratum: Five years of cancer drug approvals:innovation efficacy and costs (JAMA Oncology (2015) DOI: 10.1001/jamaoncol.2015.0373);Five years of cancer drug approvals: Innovation, efficacy, and costs

JAMA Oncology

Volumn 1, Issue 4, 2015, Pages 539-540

  Mailankody, Sham ^a   Prasad, Vinay ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COST BENEFIT ANALYSIS; DEVICE APPROVAL; DRUG COST; ECONOMIC ASPECT; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HUMAN; MASS COMMUNICATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DEVICE APPROVAL; DIFFUSION OF INNOVATION; DRUG COSTS; HUMANS; INFLATION, ECONOMIC; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84982893727     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/JAMAONCOL.2015.1424     Document Type: Erratum

References (6)

1. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum pretiu-the just price. J Clin Oncol. 2013;31(28): 3600-3604.
2. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22): 4439-4442.
3. The Economist. Hard pills to swallow: January 4, 2014. http://www.economist.com/news/international/21592655-drug-firms-have-new-medicines-and-patients-are-desperate-them-arguments-over. Accessed February 13, 2015.
4. CNN. Top industries: most profitable. http://money.cnn.com/magazines/fortune/fortune500/2009/performers/industries/profits/. Accessed February 13, 2015.
5. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626-633.
6. Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N Engl J Med. 2014;370(16):1478-1481.